These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 7822316

  • 1. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.
    Sabers CJ, Martin MM, Brunn GJ, Williams JM, Dumont FJ, Wiederrecht G, Abraham RT.
    J Biol Chem; 1995 Jan 13; 270(2):815-22. PubMed ID: 7822316
    [Abstract] [Full Text] [Related]

  • 2. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin.
    Lorenz MC, Heitman J.
    J Biol Chem; 1995 Nov 17; 270(46):27531-7. PubMed ID: 7499212
    [Abstract] [Full Text] [Related]

  • 3. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.
    Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH.
    Cell; 1994 Jul 15; 78(1):35-43. PubMed ID: 7518356
    [Abstract] [Full Text] [Related]

  • 4. Interaction between FKBP12-rapamycin and TOR involves a conserved serine residue.
    Stan R, McLaughlin MM, Cafferkey R, Johnson RK, Rosenberg M, Livi GP.
    J Biol Chem; 1994 Dec 23; 269(51):32027-30. PubMed ID: 7528205
    [Abstract] [Full Text] [Related]

  • 5. FKBP12-rapamycin target TOR2 is a vacuolar protein with an associated phosphatidylinositol-4 kinase activity.
    Cardenas ME, Heitman J.
    EMBO J; 1995 Dec 01; 14(23):5892-907. PubMed ID: 8846782
    [Abstract] [Full Text] [Related]

  • 6. Missense mutations at the FKBP12-rapamycin-binding site of TOR1.
    Freeman K, Livi GP.
    Gene; 1996 Jun 12; 172(1):143-7. PubMed ID: 8654975
    [Abstract] [Full Text] [Related]

  • 7. A mammalian protein targeted by G1-arresting rapamycin-receptor complex.
    Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL.
    Nature; 1994 Jun 30; 369(6483):756-8. PubMed ID: 8008069
    [Abstract] [Full Text] [Related]

  • 8. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex.
    Chiu MI, Katz H, Berlin V.
    Proc Natl Acad Sci U S A; 1994 Dec 20; 91(26):12574-8. PubMed ID: 7809080
    [Abstract] [Full Text] [Related]

  • 9. The rapamycin and FKBP12 target (RAFT) displays phosphatidylinositol 4-kinase activity.
    Sabatini DM, Pierchala BA, Barrow RK, Schell MJ, Snyder SH.
    J Biol Chem; 1995 Sep 08; 270(36):20875-8. PubMed ID: 7673106
    [Abstract] [Full Text] [Related]

  • 10. Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast.
    Alarcon CM, Heitman J, Cardenas ME.
    Mol Biol Cell; 1999 Aug 08; 10(8):2531-46. PubMed ID: 10436010
    [Abstract] [Full Text] [Related]

  • 11. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin.
    Zheng XF, Florentino D, Chen J, Crabtree GR, Schreiber SL.
    Cell; 1995 Jul 14; 82(1):121-30. PubMed ID: 7606777
    [Abstract] [Full Text] [Related]

  • 12. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity.
    Cafferkey R, Young PR, McLaughlin MM, Bergsma DJ, Koltin Y, Sathe GM, Faucette L, Eng WK, Johnson RK, Livi GP.
    Mol Cell Biol; 1993 Oct 14; 13(10):6012-23. PubMed ID: 8413204
    [Abstract] [Full Text] [Related]

  • 13. Mammalian RAFT1 kinase domain provides rapamycin-sensitive TOR function in yeast.
    Alarcon CM, Cardenas ME, Heitman J.
    Genes Dev; 1996 Feb 01; 10(3):279-88. PubMed ID: 8595879
    [Abstract] [Full Text] [Related]

  • 14. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue.
    Chen J, Zheng XF, Brown EJ, Schreiber SL.
    Proc Natl Acad Sci U S A; 1995 May 23; 92(11):4947-51. PubMed ID: 7539137
    [Abstract] [Full Text] [Related]

  • 15. Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells.
    Wiederrecht GJ, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT.
    Prog Cell Cycle Res; 1995 May 23; 1():53-71. PubMed ID: 9552353
    [Abstract] [Full Text] [Related]

  • 16. FAP1, a homologue of human transcription factor NF-X1, competes with rapamycin for binding to FKBP12 in yeast.
    Kunz J, Loeschmann A, Deuter-Reinhard M, Hall MN.
    Mol Microbiol; 2000 Sep 23; 37(6):1480-93. PubMed ID: 10998178
    [Abstract] [Full Text] [Related]

  • 17. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression.
    Vilella-Bach M, Nuzzi P, Fang Y, Chen J.
    J Biol Chem; 1999 Feb 12; 274(7):4266-72. PubMed ID: 9933627
    [Abstract] [Full Text] [Related]

  • 18. High-sensitivity sequencing of large proteins: partial structure of the rapamycin-FKBP12 target.
    Erdjument-Bromage H, Lui M, Sabatini DM, Snyder SH, Tempst P.
    Protein Sci; 1994 Dec 12; 3(12):2435-46. PubMed ID: 7756997
    [Abstract] [Full Text] [Related]

  • 19. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.
    Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC, Abraham RT.
    EMBO J; 1996 Oct 01; 15(19):5256-67. PubMed ID: 8895571
    [Abstract] [Full Text] [Related]

  • 20. Rapamycin resistance in ataxia-telangiectasia.
    Beamish H, Williams R, Chen P, Khanna KK, Hobson K, Watters D, Shiloh Y, Lavin M.
    Oncogene; 1996 Sep 05; 13(5):963-70. PubMed ID: 8806686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.